A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation

HIV Infections Clinical Trial

Official title:

A Phase 1, Single-center, Randomized, Open-label, Single Dose, Three-period, Balanced Crossover Study to Assess the Effect of Food on the Pediatric Dispersible Tablet Formulation of Cabotegravir and to Assess the Relative Bioavailability Between the Pediatric Dispersible Tablet (DT) Formulation and Immediate Release (IR) Tablet Formulation of Cabotegravir in Healthy Adult Participants

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05776108
• Other study ID #: 219679
• Status: Completed
• Phase: Phase 1
• Start date: March 23, 2023
• Est. completion date: June 8, 2023

Study information

• Verified date: December 2023
• Source: ViiV Healthcare
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will assess the relative bioavailability of the CAB DT formulation relative to that of the CAB IR formulation and to assess the effect of food on the CAB DT formulation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: June 8, 2023
• Est. primary completion date: June 8, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion criteria:

• Participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent form (ICF).
• Participants who are healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring (history and electrocardiogram).
• Body weight greater than or equal to (>=) 50.0 kilograms (kg) (110 pounds [lbs]) for males and >= 45 kg (99 lbs) for females and Body mass index within the range 18.5 to 31.0 kilogram per meter square (kg/m2) (inclusive) at Screening.
• Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
• Female: A female participant is eligible to participate if she is not pregnant or breastfeeding and is a Women of non child bearing potential (WONCBP) OR Is a Women of child bearing potential (WOCBP) and using a contraceptive method that is highly effective (with a failure rate of less than (<)1 percent (%) per year).
• A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention (i.e., Day-1 of each treatment Period)
• The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
• Capable of giving signed informed consent.

Exclusion Criteria:

• History or presence of/significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
• History of seizures, and participants are required to have been seizure free, off anti epileptic drugs for a minimum of 2 years and will only be considered for enrollment following discussion with the Medical Monitor
• Abnormal blood pressure as determined by the investigator.
• Medical history of cardiac arrhythmias, prior myocardial infarction in the past 3 months, or cardiac disease or a family or personal history of long QT syndrome.
• A pre-existing condition interfering with normal gastrointestinal anatomy or motility (e.g., gastroesophageal reflux disease, gastric ulcers, gastritis), hepatic and/or renal function, that could interfere with the absorption, metabolism, and/or excretion of the study intervention.
• Known suspected active Coronavirus disease 2019 (COVID-19) infection OR contact with an individual with known COVID-19 , within 14 days of study enrollment
• Any acute laboratory abnormality at screening which, in the opinion of the investigator, should preclude participation in the study of an investigational compound.
• Any Grade 2 to 4 laboratory abnormality at screening, with Creatine Phosphokinase and lipid abnormalities (e.g., total cholesterol, triglycerides), and ALT abnormalities, will exclude a participant from the study unless the investigator can provide a compelling explanation for the laboratory result(s) and has the assent of the sponsor.
• A positive test result for drugs of abuse (including marijuana), alcohol, or tobacco (indicating active current smoking) at screening or before the first dose of study intervention.
• Unable to refrain from the use of prescription or non-prescription drugs as detailed in the protocol.
• Unwillingness to abstain from excessive consumption of any food or drink detailed in the protocol.
• Would not be able to accommodate the blood loss during participation in the study
• Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day.
• Current enrollment or past participation in another investigational study as detailed in the protocol.
• Treatment with biologic agents (such as monoclonal antibodies including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing. - Current enrollment or past participation in this clinical study.
• Positive hepatitis B and/or C test result at screening or within 3 months prior to first dose of study intervention.
• Positive pre-study drug/alcohol screen, including Tetrahydrocannabinol
• Positive Human immunodeficiency virus (HIV) antibody test (4th generation assay required).
• Regular use of tobacco- or nicotine-containing products within 6 months prior to screening
• History of regular alcohol consumption within 6 months of the study,
• History of sensitivity, prior intolerance or hypersensitivity to any of the study interventions, or components thereof, or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation.
• Participant and/or his her family is part of sponsor, clinical site, third party personnel.

Related Conditions & MeSH terms

• HIV Infections

Intervention

Drug:
• Cabotegravir IR Formulation (reference)
Cabotegravir IR Formulation (reference) will be administered.
• Cabotegravir DT Formulation (test 1)
Cabotegravir DT Formulation (test 1) will be administered.
• Cabotegravir DT Formulation (test 2)
Cabotegravir DT Formulation (test 2) will be administered.

Locations

Country	Name	City	State
United States	GSK Investigational Site	Austin	Texas

Sponsors (1)

Lead Sponsor	Collaborator
ViiV Healthcare

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC[0-inf]) following administration of CAB DT after a high fat meal		Up to 168 hours
Primary	Area under the concentration time curve from time zero (pre-dose) extrapolated to last time of quantifiable concentration (AUC[0-last]) following administration of CAB DT after a high fat meal		Up to 168 hours
Primary	Maximum observed concentration (Cmax) following administration of CAB DT after a high fat meal		Up to 168 hours
Primary	AUC(0-inf) following administration of CAB DT in fasted state		Up to 168 hours
Primary	AUC(0-last) following administration of CAB DT in fasted state		Up to 168 hours
Primary	Cmax following administration of CAB DT in fasted state		Up to 168 hours
Primary	AUC(0-inf) following administration of CAB IR in fasted state		Up to 168 hours
Primary	AUC(0-last) following administration of CAB IR in fasted state		Up to 168 hours
Primary	Cmax following administration of CAB IR in fasted state		Up to 168 hours
Secondary	Apparent terminal phase half-life (T1/2) following administration of CAB DT		Up to 168 hours
Secondary	Lag time before observation of drug concentrations in sampled matrix (tlag) following administration of CAB DT		Up to 168 hours
Secondary	Time of occurrence of Cmax (Tmax) following administration of CAB DT		Up to 168 hours
Secondary	Area under the concentration time curve from time zero extrapolated to 72 hours post-dose AUC(0-72) following administration of CAB DT		Up to 72 Hours
Secondary	Concentration at 24 hours post-dose (C24) of following administration of CAB DT		At 24 Hours
Secondary	Apparent oral clearance (CL/F) following administration of CAB DT		Up to 168 hours
Secondary	Apparent volume of distribution (Vz/F) following administration of CAB DT		Up to 168 hours
Secondary	T1/2 following administration of CAB DT in fasted state		Up to 168 hours
Secondary	Tlag following administration of CAB DT in fasted state		Up to 168 hours
Secondary	Tmax following administration of CAB DT in fasted state		Up to 168 hours
Secondary	AUC(0-72) following administration of CAB DT in fasted state		Up to 72 Hours
Secondary	C24 following administration of CAB DT in fasted state		At 24 Hours
Secondary	CL/F following administration of CAB DT in fasted state		Up to 168 hours
Secondary	Vz/F following administration of CAB DT in fasted state		Up to 168 hours
Secondary	T1/2 following administration of CAB IR in fasted state		Up to 168 hours
Secondary	Tlag following administration of CAB IR in fasted state		Up to 168 hours
Secondary	Tmax following administration of CAB IR in fasted state		Up to 168 hours
Secondary	AUC(0-72) following administration of CAB IR in fasted state		Up to 72 Hours
Secondary	C24 following administration of CAB IR in fasted state		Up to 168 hours
Secondary	CL/F following administration of CAB IR in fasted state		Up to 168 hours
Secondary	Vz/F following administration of CAB IR in fasted state		Up to 168 hours
Secondary	Number of participants with Non-Serious Adverse events (AEs) and Serious adverse events (SAEs)		Up to 6 Weeks
Secondary	Number of participants with AEs by severity		Up to 6 Weeks
Secondary	Change from Baseline in Vital sign parameter: Oral Temperature (Degrees Celsius)		Baseline and Up to 6 Weeks
Secondary	Change from Baseline in Vital sign parameter: Pulse rate (Beats per minute)		Baseline and Up to 6 Weeks
Secondary	Change from Baseline in Vital sign parameter: Respiratory rate (Breaths per minute)		Baseline and Up to 6 Weeks
Secondary	Change from Baseline in Vital sign parameter: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) (Millimeters of mercury)		Baseline and Up to 6 Weeks
Secondary	Change from Baseline in Electrocardiogram (ECG) parameters: PR Interval, QRS Interval, QT Interval, Corrected QT interval using the Fridericia formula (QTcF) (Milliseconds)		Baseline and Up to 6 Weeks
Secondary	Number of participants with maximum toxicity grade increase from Baseline in hematology, chemistry and urinalysis parameters		Baseline and Up to 6 Weeks
Secondary	Change from Baseline in hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet Count (Giga cells per Liter)		Baseline and Up to 6 Weeks
Secondary	Change from Baseline in hematology parameter: Red Blood Cell Count (Trillion cells per liter)		Baseline and Up to 6 Weeks
Secondary	Change from Baseline in hematology parameter: Hemoglobin (Grams per liter)		Baseline and Up to 6 Weeks
Secondary	Change from Baseline in hematology parameter: Hematocrit (Proportion of red blood cells in blood)		Baseline and Up to 6 Weeks
Secondary	Change from Baseline in hematology parameter: Mean Corpuscular Volume (Femtoliters)		Baseline and Up to 6 Weeks
Secondary	Change from Baseline in hematology parameter: Mean Corpuscular Hemoglobin (Picograms)		Baseline and Up to 6 Weeks
Secondary	Change from Baseline in hematology parameter: Percentage of Reticulocytes (Percentage of reticulocytes)		Baseline and Up to 6 Weeks
Secondary	Change from Baseline in chemistry parameters: Creatinine, Total and Direct Bilirubin (Micromoles per liter)		Baseline and Up to 6 Weeks
Secondary	Change from Baseline in chemistry parameters: Calcium, Glucose, Potassium, Sodium, Blood urea nitrogen, Carbon dioxide (Millimoles per liter)		Baseline and Up to 6 Weeks
Secondary	Change from Baseline in chemistry parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), and Creatine phosphokinase (International units per liter)		Baseline and Up to 6 Weeks
Secondary	Change from Baseline in chemistry parameters: Total Protein (Grams per liter)		Baseline and Up to 6 Weeks
Secondary	Number of participants with abnormal urinalysis parameters		Up to 6 Weeks
Secondary	Absolute values of hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet Count (Giga cells per Liter)		Up to 6 Weeks
Secondary	Absolute values of hematology parameter: Red Blood Cell Count (Trillion cells per liter)		Up to 6 Weeks
Secondary	Absolute values of hematology parameter: Hemoglobin (Grams per liter)		Up to 6 Weeks
Secondary	Absolute values of hematology parameter: Hematocrit (Proportion of red blood cells in blood		Up to 6 Weeks
Secondary	Absolute values of hematology parameter: Mean Corpuscular Volume (Femtoliters)		Up to 6 Weeks
Secondary	Absolute values of hematology parameter: Mean Corpuscular Hemoglobin (Picograms)		Up to 6 Weeks
Secondary	Absolute values of hematology parameter: Percentage of Reticulocytes (Percentage of reticulocytes)		Up to 6 Weeks
Secondary	Absolute values of chemistry parameters: Creatinine, Total and Direct Bilirubin (Micromoles per liter)		Up to 6 Weeks
Secondary	Absolute values of chemistry parameters: Calcium, Glucose, Potassium, Sodium, Blood urea nitrogen, Carbon dioxide (Millimoles per liter)		Up to 6 Weeks
Secondary	Absolute values of chemistry parameters: ALT, ALP, AST and Creatine phosphokinase (International units per liter)		Up to 6 Weeks
Secondary	Absolute values of chemistry parameters: Total Protein (Grams per liter)		Up to 6 Weeks